Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
نویسندگان
چکیده
•Molecular testing may play a role in the determination of targeted therapy treatment options.•Targeted therapy provides treatment options for recurrent cervical cancer.•MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.
منابع مشابه
Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
MEK inhibitor (selumetinib) is a potent, orally active inhibitor of MAPK/ERK pathway. It is important to develop an accurate and robust method indicative of RAS pathway activity to stratify potential patients who can benefit from selumetinib treatment in gastric cancer (GC). First, we surveyed the sensitivity to selumetinib in a panel of 22 GC cell lines and correlated with MEK signature to sel...
متن کاملCase Report Significant response to trametinib in a woman with recurrent KRAS-mutated low-grade serous carcinoma of the ovary-a case report
Background: Invasive low-grade ovarian carcinomas differ from more common high-grade serous carcinomas in their pathogenesis, molecular markers, clinical behavior and response to treatment. KRAS gene mutations are present in 20 to 40 percent of low-grade serous ovarian cancer, and a smaller percentage of tumors with a wild-type KRAS carry BRAF gene mutations. As part of the RAS-RAF-MEK pathway,...
متن کاملکارسینوماهای نورواندوکرین، بخش ایمونوهیستوشیمی انستیتو کانسر، 79-1375
Dispersed neuroendocrine system (D.N.S) consists of a wide variety of cells that are present in the central and peripheral nervous system and in many classic endocrine organs and different tissues such as respiratory and gastrointestinal tracts, skin, prostate, breast and also their neoplasm show neuroendocrine differentiation by electron microscopy, immunohistochemistry or biochemical techniqu...
متن کاملKRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Phase II clinical trials of mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitors are ongoing and ERK1/2 activation is frequently used as a biomarker. In light of the mutational activation of BRAF and KRAS in colorectal cancer, inhibitors of the Raf-MEK-ERK mitogen-activated protein kinase are anticipated to be promising. Previous studies in pancreatic ca...
متن کاملKey roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
KRAS is frequently mutated in a variety of cancers including lung cancer. Whereas the mitogen-activated protein kinase (MAPK) is a well-known effector pathway of KRAS, blocking this pathway with MEK inhibitors is relatively ineffective. One major contributor to limited efficacy is attributed to the reactivation of MAPK signal following MEK inhibition by multiple feedback mechanisms. In a recent...
متن کامل